Ken Cohen, MD, director of translational research for Optum Care, speaks on the future of more biosimilars hitting the market, and how they will influence value-based care.
Ken Cohen, MD, director of translational research for Optum Care, speaks on the future of more biosimilars hitting the market, and how they will influence value-based care.
Transcript
As more and more biosimilars are hitting the market, how is the approach to biosimilars changing? And how will the approach of prescribing a biologic versus a biosimilar change?
Being able to differentiate between biosimilars won't be possible, because large [randomized controlled trials] for each of those biosimilars have not been done in head-to-head comparative fashion. There is recognition that the clinical efficacy of those is equivalent and, therefore, it will come back to market powers in terms of cost and availability.
There will be gaming of the system where the branded agents will try to leverage formulary placement with access to their other drugs and other things that pharma has done over the years to try to protect branded agents. I think in a value-based world, you make the best decision based on the individual cost effectiveness of a single product. Over time, I think that will create the landscape where biosimilars can gain footing and ultimately decrease cost of care for patients.
Moving Evidence From Research to Practice: Q&A With Ken Cohen, MD
June 23rd 2025In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Ken Cohen, MD, executive director of translational research at Optum Health.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More